Retraction: Rescue of MHC-1 antigen processing machinery by down-regulation in expression of IGF-1 in human glioblastoma cells (PLoS ONE (2013) 8:3 (e58428) DOI: 10.1371/journal.pone.0058428);Rescue of MHC-1 Antigen Processing Machinery by Down-Regulation in Expression of IGF-1 in Human Glioblastoma Cells

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Pan, Yuexin ^a,b   Trojan, Jerzy ^c   Guo, Yajun ^d   Anthony, Donald D ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c INSERM   (France)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; LARGE MULTICATALYTIC PROTEASOME 2; LARGE MULTICATALYTIC PROTEASOME 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; MESSENGER RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAT1 PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84875196199     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0305595     Document Type: Erratum

References (46)

1. Monaco JJ, (1995) Pathways for the processing and presentation of antigens to T cells. J Leukoc Biol 57: 543-547.
2. Hofmann M, Nussbaum AK, Emmerich NP, Stoltze L, Schild H, (2001) Mechanisms of MHC class I-restricted antigen presentation. Expert Opin Ther Targets 5: 379-393.
3. Flutter B, Gao B, (2004) MHC Class I antigen presentation - recently trimmed and well presented. Cell Mol Immunol 1: 22-30.
4. Groettrup M, van den Broek M, Schwartz K, Macagno A, Khan S, et al. (2001) Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol 21: 339-358.
5. Niedermann G, (2002) Immunological functions of the proteasome. Curr Top Microbiol Immunol 268: 91-136.
6. Lankat-Buttgereit B, Tampe R, (1999) The transporter associated with antigen processing TAP: structure and function. FEBS Lett 464: 108-112.
7. Abele R, Tampe R, (2006) Modulation of the antigen transport machinery TAP by friends and enemies. FEBS Lett 580: 1156-1163.
8. Cresswell P, Banggia N, Dick T, Diedrich G, (1999) The nature of the MHC Class I peptide loading complex. Immunol Rev 172: 21-28.
9. Raghavan M, Del Cid N, Rizvi MS, Peters RL, (2008) MHC class 1 assembly: Out and about. Trends Immunology 29: 436-443.
10. Seliger B, Maeurer MJ, Ferrone S, (1997) TAP off - tumor on. Immunol Today 18: 292-299.
11. Thor Straaten P, Kirkin AF, Seremet T, Zeuthen J, (1997) Expression of transporter associated with antigen processing 1 and 2 (TAP 1/2) in malignant melanoma cell lines. Int J Cancer 70: 582-586.
12. Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, et al. (1998) HLA class 1 antigen and transporter associated with antigen processing (TAP 1 and TAP 2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 58: 737-742.
13. Alyssa J, France J, Sy MS, Harding CV, (1998) Down-regulation of the transporter for antigen presentation, proteasome subunits, and class 1 major histocompatibility complex in tumor cell lines. Cancer Res 58: 3600-3667.
14. Murray JL, Hunson JM, Ross MI, Zhang HZ, Ioannides CG, (2000) Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression. J Immunother 23: 28-35.
15. Trojan J, Johnson T, Rudin S, Ilan J, Tykocinski M, et al. (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor 1 RNA. Science 259: 94-97.
16. Trojan J, Johnson TR, Rudin SD, Blossey BK, Anthony DD, et al. (1994) Gene therapy of murine teratocarcinoma: separate functions for insulin-like growth factors 1 and 2 in immunogenicity and differentiation. Proc Natl Acad Sci USA 91: 6088-6092.
17. Upegui-Gonzalez LC, Ly A, Duc HT, Pan Y, Anthony D, et al. (2001) IGF-1 triple helix strategy in hepatoma treatment. Hepatogastroenterology. 48: 660-666.
18. Lafarge-Frayssinet C, Due HT, Frayssinet C, Sarasin A, Anthony D, et al. (1997) Antisense insulin-like growth factor 1 transferred into a rat hepotoma cell line inhibits tumorigenesis by modulating major histocompatibility complex 1 cell surface expression. Cancer Gene Ther 4: 276-285.
19. Trojan J, Duc HT, Upegui-Gonzalez LC, Gou Y, Anthony D, et al. (1996) Presence of MHC-1 and B-7 molecules in rat and human glioma cells expressing antisense IGF-1 mRNA. Neurosci Lett 212: 9-12.
20. Anthony DD, Pan YX, Wu SG, Shen F, Guo YJ, (1998) Ex vivo and in vivo anti-sense RNA strategies for treatment of cancer in humans. Adv Exp Med Biol 451: 27-34.
21. Liu Y, Trojan J, Habib N, Anthony DD, Wu M, et al. (2000) Enhancement of immunogenicity of tumor cells by co-transfection with gene encoding antisense insulin-like growth factor-1 and B7.1 molecules. Cancer Gene Ther 7: 456-465.
22. Pan YX, Anthony DD, (2000) IGF-1 antisense strategies for cancer treatment. Methods Mol Med 35: 189-204.
23. Yates JL, Warren N, Sugden B, (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313: 812-815.
24. Trojan J, Blossey B, JohnsonT, Rudin S, Tykocinski M, et al. (1992) Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor 1. Proc Natl Acad Sci U S A 89: 4874-4878.
25. LY A, Bouchaud C, Henin D, Pan Y, Anthony D, et al. (2000) Expression of insulin-like growth factor-1 in rat glioma cells is associated with change in both immunogenicity and apoptosis. Neurosci Lett 281: 13-16.
26. Ly A, Duc HT, Kalamarides M, Francois JC, Anthony D, et al. (2001) Human glioma cells transformed by IGF-1 triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma. Mol Pathol 54: 230-239.
27. Kamarashev J, Ferrone S, Boni R, Nestle FO, Burg G, et al. (2001) TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer 95: 23-28.
28. Lankat-Buttgereit B, Tampe R, (2002) The transporter associated with antigen processing: function and implications in human diseases. Physiol Rev 82: 187-204.
29. Petersson M, Charo J, Salazar-Onfray F, Noffz G, Mohaupt M, et al. (1998) Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class 1 expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 161: 2099-2105.
30. Gibson JM, Aplin JD, White A, Westwood M, (2001) Regulation of IGF bioavailability in pregnancy. Mol Hum Reprod 7: 79-87.
31. Baik I, Devito WJ, Ballen K, Becker PS, Okulicz W, et al. (2005) Association of fetal hormone levels with stem cell potential: evidence for early life roots of human cancer. Cancer Res 65: 358-363.
32. Gustafsson C, Mjosberg J, Matussek A, Geffers R, Matthiesen L, et al. (2008) Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. PloS One 3: e2078.
33. Seliger B, Ritz U, Abele R, Bock M, Tampe R, et al. (2001) Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class 1 antigen processing pathway. Cancer Res 61: 8647-8650.
34. Guo Y, Yang T, Liu X, Lu S, Wen J, et al. (2002) Cis elements for transporter associated with antigen-processing-2 transcription: two new promoters and an essential role of the IFN response factor binding element in IFN-gamma-mediated activation of the transcription initiator. Int Immunol 14: 189-200.
35. Procko E, Gaudet R, (2009) Antigen processing and presentation: TAPing into ABC transporters. Curr Opin Immunol 21: 84-91.
36. Matsui M, Machida S, Itani-Yohda T, Akatsuka T, (2002) Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma. J Gastroenterol Hepatol 17: 897.
37. Cramer LA, Nelson SL, Klemsz MJ, (2000) Synergistic induction of the Tap-1 gene by IFN-gamma and lipopolysaccharide in macrophages is regulated by STAT1. J Immunol 165: 3190--3197.
38. Chatterjee-Kishore M, Kishore R, Hicklin DJ, Marincola FM, Ferrone S, (1998).
39. Different requirements for signal transducer and activator of transcription 1α and interferon requlatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem 273: 16177-16183.
40. Beck S, Abdulla S, Alderton RP, Glynne RJ, Gut IG, et al. (1996) Evolutionary dynamics of non-coding sequences within the class II region of the human MHC. J Mol Biol 255: 1-13.
41. Brucet M, Marques L, Sebastian C, Lloberas J, Celada A, (2004) Regulation of murine Tap 1 and Lmp 2 genes in macrophages by interferon gamma is mediated by STAT1 and IRF-1. Genes Immun 5: 26-35.
42. De La Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, et al. (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22: 449-462.
43. Li P, Harris D, Liu Z, Liu J, Keating M, et al. (2010) Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One 5: e11859.
44. Giuliani C, Saji M, Bucci I, Fiore G, Liberatore M, et al. (2006) Transcriptional regulation of major histocompatibility complex class I gene by insulin and IGF-1 in FRTL-5 thyroid cells. J Endocrinol 189: 605-615.
45. Ma X, Bai Y, (2012) IGF-1 activates the PI3K/AKT signaling pathway via upregulation of secretory clusterin. Mol Med Report 6: 1433-1437.
46. Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, at al, (2012) Expression of MHC class 1 on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology 1: 1104-1110.